Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Core Insights - Aligos Therapeutics, Inc. has appointed Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs, effective immediately, to enhance its leadership team during the development of ALG-000184 [1][2] - Dr. Polo brings extensive regulatory expertise from his previous roles at Shionogi Inc. and Johnson & Johnson, where he managed global regulatory strategies and played a key role in the COVID-19 vaccine rollout [2][3] Company Overview - Aligos Therapeutics is a clinical stage biotechnology company focused on developing therapies for liver and viral diseases, with a mission to improve patient outcomes [3] - The company is advancing a pipeline targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3]